100s of titles, one news app for just $10 a month.
Dive Deeper:
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Salarius Pharmaceuticals Successfully Completes pre-IND Meeting with FDA for SP-3164
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) successfully completed the pre-IND (Investigational New Drug) meeting process with the U.S. Food and Drug Administration…
FDA Clears Regulus Therapeutics' IND for RGLS8429 In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc. (NASDAQ: RGLS) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug…
Stealth BioTherapeutics Shares Rally following FDA Orphan Drug Designation To Elamipretide For Duchenne muscular dystrophy (DMD)
Stealth BioTherapeutics Corp (NASDAQ: MITO) received Orphan Drug Designation to Elamipretide from the United States Food and Drug Administration (FDA)…
One subscription that gives you access to news from hundreds of sites
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
PolarityTE Shares Jump After FDA Regenerative Medicine Advanced Therapy Designation (RMAT) for SkinTE
The U.S. Food and Drug Administration (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to PolarityTE’s (NASDAQ: PTE) …
Get all your news in one place
Latest Technology news:
'God of War: Ragnarok' update proves 'TLOU 2' changed Sony forever
'God of War: Ragnarok' is one of the most anticipated games of 2022, and a new update from Sony shows…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Vipshop First-Quarter Results Miss On Revenue As Active Users Decline
VIPS stock climbed as the China e-commerce company reported first-quarter results that fell short on revenue but beat on earnings.
Framework is upgrading its modular laptop with 12th Gen Intel chips
Framework improved the build quality of its laptop case and is offering an easy way to upgrade your old model…
'Fortnite' Supply Llama Challenge: How to unlock exclusive rewards on PlayStation
Participating in the new 'Fortnite' Supply Llama Challenge isn't as straightforward as you'd expect. Here's how to begin the event…
Kia To Make Purpose Built EVs At New Korea Plant From 2025
Kia's electric Purpose Built Vehicles will be based on a new eS scalable skateboard platform developed specifically for PBVs.
From analysis to good news, read the world’s best news in one place
WhatsApp to Launch Cloud API, Premium Features to Attract Businesses
WhatsApp is introducing free cloud-based API services in a push to get more businesses using the app, Meta Platforms CEO…
Nissan Soon To Announce US Battery Supplier For Next-Gen EVs
Nissan is expected to announce a new US battery supplier for its next-generation electric vehicles, which will be introduced later…

Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested

By Fermin Orgambide

On Wednesday, May 18, Clearmind Medicine Inc. (OTC:CMNDF) will meet with the Center for Drug Evaluation and Research (CDER), a department within the FDA.

The objective of the meeting is to discuss Clearmind’s proposed first-in-human study evaluating its proprietary drug candidate CMND-100, developed for the treatment of alcohol use disorder. Clearmind could later submit an investigational new drug application.

CMND-100, the company’s flagship compound, reportedly produces a reduction in the desire of consuming alcohol. According to the company, the substance could innervate “neural pathways such as 5-HT1A that lead to ‘sensible behavior.’”

Dr. Adi Zuloff-Shani, Clearmind’s CEO commented: “We recently submitted questions to the FDA as part of our pre-IND submission package. With answers to these questions and any additional information provided by the FDA during the meeting, we will be in position to address any open issues or requests of the FDA before submitting our IND.”

Pre-clinical data for the compound is promisingAnother study, done in collaboration with SciSparc Ltd. (NASDAQ:SPRC), showed that combining CMND-100 with SciSparc's CannAmide could also be beneficial when treating alcoholism.

Photo: Courtesy of DiamondRehab Thailand on Unsplash

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Salarius Pharmaceuticals Successfully Completes pre-IND Meeting with FDA for SP-3164
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) successfully completed the pre-IND (Investigational New Drug) meeting process with the U.S. Food and Drug Administration…
FDA Clears Regulus Therapeutics' IND for RGLS8429 In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc. (NASDAQ: RGLS) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug…
Stealth BioTherapeutics Shares Rally following FDA Orphan Drug Designation To Elamipretide For Duchenne muscular dystrophy (DMD)
Stealth BioTherapeutics Corp (NASDAQ: MITO) received Orphan Drug Designation to Elamipretide from the United States Food and Drug Administration (FDA)…
One subscription that gives you access to news from hundreds of sites
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
PolarityTE Shares Jump After FDA Regenerative Medicine Advanced Therapy Designation (RMAT) for SkinTE
The U.S. Food and Drug Administration (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to PolarityTE’s (NASDAQ: PTE) …
Get all your news in one place